ArticleWorld journal of microbiology & biotechnology2026
Targeted gene expression and associated metabolomic insights into Bacillus subtilis LBS5-mediated suppression of Candidatus liberibacter asiaticus in acid lime (Citrus aurantiifolia (christm.) swingle).
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Citrus Greening Disease (CGD), caused by Candidatus Liberibacter asiaticus (CLas), severely impairs citrus growth and productivity. Among five Bacillus isolates from acid lime leaves, Bacillus subtilis LBS5 exhibited superior plant growth-promoting traits, including a glucanolytic index of 5.85, siderophore production of 9.85 µmol/ml, IAA synthesis of 28.67 µg/ml, and phosphate solubilization of 249.34 µg/ml. LBS5 inhibited the surrogates, Xanthomonas citri and Agrobacterium tumefaciens with inhibition zones of 1.15 cm and 1.06 cm, respectively, and significantly reduced CLas titres from 6.33 ± 0.04 × 10⁸ to 9.15 ± 0.05 × 10³ copies within five days, comparable to tetracycline ((2.75 ± 0.91) × 10⁴). Gene expression analysis revealed marked upregulation of defense-related genes, PAL (5.87-17.05-fold) and PR2 (3.87-16.05-fold), indicating activation of phenylpropanoid and glucanase-mediated defense pathways. Integrated metabolomic and pathway analyses, including PLS-DA, demonstrated coordinated upregulation of PAL (2.08 log₂FC) and PR2 (2.65 log₂FC), accumulation of phenylpropanoid metabolites such as quinic acid (6.17 log₂FC), coumaric acid (2.62 log₂FC), and phenylalanine (1.36 log₂FC), and modulation of carbohydrate and antioxidant metabolism. FTIR and ¹H NMR analyses confirmed reduced lipid oxidation and lignin deposition, along with enhanced defense-related metabolites. Collectively, LBS5 effectively suppresses CLas, activates key defense pathways, and enhances metabolite-mediated resistance, highlighting its potential as a biocontrol and plant growth-promoting agent for sustainable management of CGD.
Indexed as
Identifiers
41652096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.